Form 4: Emergent BioSolutions Director Receives Stock Grant and Options

Marvin L. White, a Director at Emergent BioSolutions Inc. (EBS), was granted restricted stock units and stock options on April 30, 2026, as part of his compensation for board service.

Summary

• Director Marvin L. White received a grant of 25,344 restricted stock units (RSUs) and 11,296 stock options on April 30, 2026.
• The RSUs and stock options are part of his compensation for serving on the Board and its committees.
• The RSUs represent a right to receive one share of Emergent BioSolutions common stock upon vesting.
• The stock options grant the right to purchase one share of common stock at an exercise price of $7.99 upon vesting.
• Both the RSUs and stock options are subject to vesting conditions, requiring Mr. White to remain a director through the annual grant vesting date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine director compensation and does not contain new financial performance data or strategic shifts.

Positives

• Director compensation includes equity awards, aligning director interests with shareholders.
• The grant of RSUs and stock options indicates continued confidence in the company's long-term value by a board member.
• The exercise price for stock options is set, providing a clear potential return for the director based on future stock performance.

Risks

• Vesting of RSUs and stock options is contingent on the reporting person remaining a director through the annual grant vesting date, implying potential departure risk.
• The value of the RSUs and stock options is subject to the future performance of Emergent BioSolutions' stock price.

Future Outlook

The future outlook for the granted RSUs and stock options is dependent on the reporting person remaining a director and the company's stock performance, with options expiring in April 2033.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biopharmaceutical industry to incentivize long-term commitment and align executive interests with shareholder value. The specific structure of these grants, including vesting schedules and exercise prices, can vary significantly between companies.

Stakeholder Impact

• Shareholders: The equity grants align director incentives with shareholder interests, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacting employees, such grants are part of the overall compensation structure that can influence company culture and performance.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Reporting person must remain a director through the annual grant vesting date for RSUs and stock options to vest.
• Stock options can be exercised at $7.99 per share after vesting until their expiration in April 2033.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Director Compensation, Restricted Stock Units, Stock Options, Beneficial Ownership, SEC Filing, Marvin L White